Lihau Yu

Jun 15, 2018

Eisai announced today that it has appointed Lihau as president and chief data sciences officer of H3 Biomedicine, the cancer genomics-based drug discovery company of Eisai. Yu will be responsible for the overall scientific and business direction of H3, where she joined H3 in 2011. Yu previously spent 12 years at AstraZeneca.